Biblio
“APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
, “Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways.”, Proc Natl Acad Sci U S A, vol. 107, no. 28, pp. 12698-703, 2010.
, “Memory impairment in transgenic Alzheimer mice requires cellular prion protein.”, J Neurosci, vol. 30, no. 18, pp. 6367-74, 2010.
, “18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.”, Brain, vol. 134, no. Pt 4, pp. 1089-100, 2011.
, “Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease.”, Lancet Neurol, vol. 10, no. 2, pp. 187-98, 2011.
, “Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.”, Sci Transl Med, vol. 3, no. 89, p. 89ra57, 2011.
, “Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.”, J Neuropathol Exp Neurol, vol. 70, no. 11, pp. 960-9, 2011.
, “Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.”, J Clin Invest, vol. 122, no. 4, pp. 1316-38, 2012.
, “An epigenetic blockade of cognitive functions in the neurodegenerating brain.”, Nature, vol. 483, no. 7388, pp. 222-6, 2012.
, “Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.”, Arch Neurol, vol. 69, no. 5, pp. 636-43, 2012.
, “National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.”, Alzheimers Dement, vol. 8, no. 1, pp. 1-13, 2012.
, “An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.”, Ann Neurol, vol. 71, no. 6, pp. 765-75, 2012.
, “A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β.”, Sci Transl Med, vol. 4, no. 147, p. 147ra111, 2012.
, “Predicting regional neurodegeneration from the healthy brain functional connectome.”, Neuron, vol. 73, no. 6, pp. 1216-27, 2012.
, “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
, “Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease.”, Cell, vol. 153, no. 3, pp. 707-20, 2013.
, “TREM2 variants in Alzheimer's disease.”, N Engl J Med, vol. 368, no. 2, pp. 117-27, 2013.
, “REST and stress resistance in ageing and Alzheimer's disease.”, Nature, vol. 507, no. 7493, pp. 448-54, 2014.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Aberrant Spontaneous Brain Activity in Patients with Mild Cognitive Impairment and concomitant Lacunar Infarction: A Resting-State Functional MRI Study.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1243-54, 2016.
, “Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1143-59, 2016.
, “Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).”, J Alzheimers Dis, vol. 49, no. 2, pp. 287-300, 2016.
, “Aging as a Precipitating Factor in Chronic Restraint Stress-Induced Tau Aggregation Pathology, and the Protective Effects of Rosmarinic Acid.”, J Alzheimers Dis, vol. 49, no. 3, pp. 829-44, 2016.
, “The Anti-Amyloid-β Monoclonal Antibody 4G8 Recognizes a Generic Sequence-Independent Epitope Associated with α-Synuclein and Islet Amyloid Polypeptide Amyloid Fibrils.”, J Alzheimers Dis, vol. 50, no. 2, pp. 517-25, 2016.
, “Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1085-97, 2016.
,